Table 8 Type of hormonal therapy administered according to menopausal status in 346 pT1a and pT1b tumours
From: Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
Premenopausal (N = 89) | Postmenopausal (N = 257) | |
|---|---|---|
Hormonal therapy | ||
Tamoxifen 5 y | 11 (12.3%) | 35 (13.6%) |
Tamoxifen 5 y + LHRH | 65 (73.0%) | 0 (0.0%) |
Tamoxifen 2-3y→Aromatase Inhibitor 3–2 y | 3 (3.3%) | 44 (17.1%) |
Aromatase Inhibitor 5 y | 1 (1.1%) | 173 (67.3%) |
Aromatase Inhibitor 5 y + LHRH | 6 (6.7%) | 1 (0.4%) |
LHRH alone | 1 (1.1%) | 0 (0.0%) |
Other | 2 (2.2%) | 4 (1.6%) |